Organogenesis (NASDAQ:ORGO) Downgraded to Hold Rating by Wall Street Zen

Organogenesis (NASDAQ:ORGO) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “hold” rating in a research note issued on Saturday.

ORGO has been the subject of several other research reports. BTIG Research dropped their price target on shares of Organogenesis from $9.00 to $8.00 and set a “buy” rating for the company in a research note on Friday. Weiss Ratings restated a “sell (d+)” rating on shares of Organogenesis in a report on Monday, December 29th. Two investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Organogenesis has a consensus rating of “Hold” and an average price target of $7.67.

Organogenesis Stock Performance

NASDAQ ORGO opened at $3.21 on Friday. The company has a market cap of $407.38 million, a P/E ratio of 40.13 and a beta of 1.46. The company has a debt-to-equity ratio of 0.01, a current ratio of 3.32 and a quick ratio of 2.88. The stock has a 50-day moving average of $4.23 and a two-hundred day moving average of $4.59. Organogenesis has a 1-year low of $2.61 and a 1-year high of $7.08.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Thursday, February 26th. The company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.10. The business had revenue of $225.61 million for the quarter, compared to analysts’ expectations of $172.68 million. Organogenesis had a net margin of 5.32% and a return on equity of 22.64%. As a group, analysts anticipate that Organogenesis will post -0.07 EPS for the current year.

Insiders Place Their Bets

In other Organogenesis news, Director Glenn H. Nussdorf sold 200,000 shares of Organogenesis stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $5.14, for a total transaction of $1,028,000.00. Following the completion of the sale, the director directly owned 2,565,591 shares of the company’s stock, valued at $13,187,137.74. The trade was a 7.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 33.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Organogenesis

Several hedge funds and other institutional investors have recently made changes to their positions in ORGO. Quarry LP purchased a new stake in Organogenesis during the third quarter worth approximately $25,000. State of Alaska Department of Revenue acquired a new stake in Organogenesis during the third quarter worth approximately $25,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Organogenesis during the 4th quarter worth approximately $34,000. Federated Hermes Inc. boosted its holdings in shares of Organogenesis by 52.8% in the 4th quarter. Federated Hermes Inc. now owns 8,541 shares of the company’s stock valued at $44,000 after buying an additional 2,953 shares in the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new position in shares of Organogenesis in the 4th quarter valued at $57,000. Institutional investors and hedge funds own 49.57% of the company’s stock.

Organogenesis News Summary

Here are the key news stories impacting Organogenesis this week:

• Positive Sentiment: Record Q4 results — Organogenesis reported Q4 revenue of $225.6M (big beat) and EPS that topped estimates, with strong gross‑profit and operating‑profit expansion and materially higher operating cash flow. This explains recent upside in sentiment from the quarter’s beat. Organogenesis Reports Fourth Quarter 2025 Financial Results
• Neutral Sentiment: Analyst price‑target adjustment — BTIG trimmed its target from $9.00 to $8.00 but maintained a Buy rating, still implying substantial upside from today’s price. This keeps some analyst support but signals more cautious optimism. BTIG Price Target Update via Benzinga
• Negative Sentiment: Weak FY‑2026 guidance — management issued revenue guidance of $350M–$420M for FY‑2026, well below consensus (~$543M). The large gap between the outlook and street expectations is the primary driver of the stock weakening today. FY‑2026 Guidance and Earnings Release (MarketBeat)
• Negative Sentiment: Insider and institutional flows — notable insider selling (reported large insider sales) and mixed institutional activity (some large redemptions/position cuts) may add selling pressure or indicate some investors are booking gains after the strong quarter. QuiverQuant Coverage of Q4 Results & Insider Activity

Organogenesis Company Profile

Organogenesis Inc operates as a regenerative medicine company focused on the development, manufacturing and commercialization of therapeutic solutions for wound care, surgical repair and sports medicine. The company’s product portfolio addresses a range of acute and chronic tissue repair needs, leveraging bioengineered skin substitutes, human placental-derived products and other allografts designed to promote healing and reduce scarring. Organogenesis markets its therapies to hospitals, outpatient clinics, wound care centers and other healthcare providers.

Key offerings include Apligraf, a living skin substitute for treatment of diabetic foot ulcers and venous leg ulcers; Dermagraft, a cryopreserved human fibroblast-derived dermal substitute; Grafix, a placental membrane allograft for complex and chronic wounds; and TheraSkin, a cryopreserved human skin allograft used in surgical and reconstructive procedures.